2022
DOI: 10.1080/0886022x.2022.2043903
|View full text |Cite
|
Sign up to set email alerts
|

Proton pump inhibitor usage is associated with higher all-cause mortality and CV events in peritoneal dialysis patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

0
3
0

Year Published

2023
2023
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 30 publications
0
3
0
Order By: Relevance
“…37,38 PPIs were also found in vivo to affect markers of endothelial health. 38 However, confounding by indication can be a significant limitation, and the risks of peritonitis and mortality with PPI use across studies might be a marker of comorbidity and frailty among PPI users.…”
Section: Discussionmentioning
confidence: 98%
See 2 more Smart Citations
“…37,38 PPIs were also found in vivo to affect markers of endothelial health. 38 However, confounding by indication can be a significant limitation, and the risks of peritonitis and mortality with PPI use across studies might be a marker of comorbidity and frailty among PPI users.…”
Section: Discussionmentioning
confidence: 98%
“…PPI users had a 47% higher risk of all-cause mortality and 80% more CV events. 38 The mechanism for higher risk of death and CV morbidity are poorly understood but may include occurrence of adverse effects, such as infections, osteoporosis and fractures, hypomagnesemia, or reduced efficacy of some antiplatelet therapy in the context of drug–drug interactions. 37 , 38 PPIs were also found in vivo to affect markers of endothelial health.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation